Cargando…
Insulinoma With Concomitant Insulin Antibodies
OBJECTIVE: The coexistence of insulinoma and insulin antibodies is extremely rare. The aim of this novel case report is to inform physicians of the possibility of an insulinoma with concomitant insulin antibodies. METHODS: In this report, we describe a patient with symptomatic hypoglycemia confirmed...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association of Clinical Endocrinology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282515/ https://www.ncbi.nlm.nih.gov/pubmed/34307846 http://dx.doi.org/10.1016/j.aace.2021.01.009 |
_version_ | 1783723029408251904 |
---|---|
author | Iqbal, Anira Broome, David T. Makin, Vinni Yogi-Morren, Divya |
author_facet | Iqbal, Anira Broome, David T. Makin, Vinni Yogi-Morren, Divya |
author_sort | Iqbal, Anira |
collection | PubMed |
description | OBJECTIVE: The coexistence of insulinoma and insulin antibodies is extremely rare. The aim of this novel case report is to inform physicians of the possibility of an insulinoma with concomitant insulin antibodies. METHODS: In this report, we describe a patient with symptomatic hypoglycemia confirmed with a 72-hour fast, who was subsequently found to have an insulinoma with concomitant elevation in his immunoglobulin G insulin antibody titer. RESULTS: The patient presented with initial symptoms of diaphoresis, confusion, and disorientation and was found unresponsive by a bystander. He had a fingerstick blood glucose of 36 mg/dL (reference 74-99 mg/dL), without exogenous insulin or sulfonylurea use. His symptoms resolved with administration of glucose. He was subsequently admitted for a 72-hour fast in which he developed neuroglycopenic symptoms 4 hours into the fast with fingerstick glucose of 47 mg/dL and serum glucose of 44 mg/dL (reference 74-99 mg/dL), C-peptide of 10.8 ng/mL (reference 0.5-2.7 ng/mL), insulin level of 106 μIU/mL (reference <25 μIU/mL), and a proinsulin level of 675 pmol/mL (reference <22 pmol/mL). His insulin-to-C-peptide ratio was 0.20, in which a ratio <1 is indicative of an insulinoma. Endoscopic ultrasound demonstrated a 16 x 11 mm biopsy-proven neuroendocrine tumor. He was found to have a high titer insulin antibody titer at 2.4 U/mL (reference <0.4 U/mL), was started on prednisone, and underwent successful radiofrequency ablation. He was able to be successfully tapered off steroids without recurrence. CONCLUSION: The coexistence of insulinoma with insulin antibodies is novel, and to our knowledge, has never been published. |
format | Online Article Text |
id | pubmed-8282515 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Association of Clinical Endocrinology |
record_format | MEDLINE/PubMed |
spelling | pubmed-82825152021-07-22 Insulinoma With Concomitant Insulin Antibodies Iqbal, Anira Broome, David T. Makin, Vinni Yogi-Morren, Divya AACE Clin Case Rep Case Report OBJECTIVE: The coexistence of insulinoma and insulin antibodies is extremely rare. The aim of this novel case report is to inform physicians of the possibility of an insulinoma with concomitant insulin antibodies. METHODS: In this report, we describe a patient with symptomatic hypoglycemia confirmed with a 72-hour fast, who was subsequently found to have an insulinoma with concomitant elevation in his immunoglobulin G insulin antibody titer. RESULTS: The patient presented with initial symptoms of diaphoresis, confusion, and disorientation and was found unresponsive by a bystander. He had a fingerstick blood glucose of 36 mg/dL (reference 74-99 mg/dL), without exogenous insulin or sulfonylurea use. His symptoms resolved with administration of glucose. He was subsequently admitted for a 72-hour fast in which he developed neuroglycopenic symptoms 4 hours into the fast with fingerstick glucose of 47 mg/dL and serum glucose of 44 mg/dL (reference 74-99 mg/dL), C-peptide of 10.8 ng/mL (reference 0.5-2.7 ng/mL), insulin level of 106 μIU/mL (reference <25 μIU/mL), and a proinsulin level of 675 pmol/mL (reference <22 pmol/mL). His insulin-to-C-peptide ratio was 0.20, in which a ratio <1 is indicative of an insulinoma. Endoscopic ultrasound demonstrated a 16 x 11 mm biopsy-proven neuroendocrine tumor. He was found to have a high titer insulin antibody titer at 2.4 U/mL (reference <0.4 U/mL), was started on prednisone, and underwent successful radiofrequency ablation. He was able to be successfully tapered off steroids without recurrence. CONCLUSION: The coexistence of insulinoma with insulin antibodies is novel, and to our knowledge, has never been published. American Association of Clinical Endocrinology 2021-02-03 /pmc/articles/PMC8282515/ /pubmed/34307846 http://dx.doi.org/10.1016/j.aace.2021.01.009 Text en © 2021 AACE. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Iqbal, Anira Broome, David T. Makin, Vinni Yogi-Morren, Divya Insulinoma With Concomitant Insulin Antibodies |
title | Insulinoma With Concomitant Insulin Antibodies |
title_full | Insulinoma With Concomitant Insulin Antibodies |
title_fullStr | Insulinoma With Concomitant Insulin Antibodies |
title_full_unstemmed | Insulinoma With Concomitant Insulin Antibodies |
title_short | Insulinoma With Concomitant Insulin Antibodies |
title_sort | insulinoma with concomitant insulin antibodies |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8282515/ https://www.ncbi.nlm.nih.gov/pubmed/34307846 http://dx.doi.org/10.1016/j.aace.2021.01.009 |
work_keys_str_mv | AT iqbalanira insulinomawithconcomitantinsulinantibodies AT broomedavidt insulinomawithconcomitantinsulinantibodies AT makinvinni insulinomawithconcomitantinsulinantibodies AT yogimorrendivya insulinomawithconcomitantinsulinantibodies |